Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 05, 2022 07:00 ET | Source: Skye Bioscience, Inc.

Skye Bioscience Reports Enhanced Intraocular Pressure-Lowering of SBI-100 Formulation Published in Peer-Reviewed Journal

San Diego, California, May 05, 2022 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye” or the “Company”), a pharmaceutical company developing proprietary, synthetic cannabinoid...
April 28, 2022 07:00 ET | Source: Skye Bioscience, Inc.

Skye Bioscience Engages Clinical Trial Site for Phase 1 Study in Agreement with CMAX Clinical Research

San Diego, California, April 28, 2022 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye” or the “Company”), a pharmaceutical company developing proprietary, synthetic cannabinoid...
March 03, 2022 08:30 ET | Source: Skye Bioscience, Inc.

Skye Bioscience Retains Novotech as CRO for Phase 1 Trial of Glaucoma Drug Candidate

San Diego, Calif, March 03, 2022 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“SKYE” or the “Company”), a biopharmaceutical company developing proprietary, synthetic cannabinoid-derived...
February 16, 2022 08:30 ET | Source: Skye Bioscience, Inc.

Skye Bioscience Reports Positive Results for SBI-100 in GLP Toxicology Study

Initiation of Phase 1 clinical trial of SBI-100 ophthalmic nanoemulsion expected in the second quarter of 2022 SAN DIEGO, CA, Feb. 16, 2022 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB:...
February 01, 2022 08:30 ET | Source: Skye Bioscience, Inc.

Skye Bioscience Reports Potential Neuroprotective Benefit of SBI-100 In Preclinical Glaucoma Model

SAN DIEGO, CA, Feb. 01, 2022 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye” or the “Company”), a pharmaceutical company developing proprietary, synthetic cannabinoid-derived...
January 10, 2022 07:00 ET | Source: Skye Bioscience, Inc.

Skye Bioscience Issues Shareholder Letter Providing Progress Update and Business Outlook for 2022

SAN DIEGO, CA, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye”), a pharmaceutical company developing proprietary, synthetic, cannabinoid-derived molecules to treat...
January 04, 2022 08:30 ET | Source: Skye Bioscience, Inc.

Skye Bioscience to Present at H.C. Wainwright BIOCONNECT Virtual Conference

SAN DIEGO, CA, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye”), a biopharmaceutical company developing proprietary, synthetic, cannabinoid-derived molecules to treat...
December 15, 2021 08:30 ET | Source: Skye Bioscience, Inc.

Skye Bioscience Expands Board of Directors with the Appointment of Life Sciences Executive Keith W. Ward, PhD

Skye Bioscience Announces Promotion of Tu Diep, MSc to Chief Development Officer SAN DIEGO, CA, Dec. 15, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the...
October 21, 2021 08:30 ET | Source: Skye Bioscience, Inc.

Skye Bioscience Sponsored Research Presented at American Association of Pharmaceutical Scientists Meeting PharmSci 360

SAN DIEGO, CA, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye” or the “Company”), a biopharmaceutical company developing proprietary, synthetic cannabinoid-derived...
October 12, 2021 13:35 ET | Source: Skye Bioscience, Inc.

Skye Bioscience Establishes New Cannabinoid Pharmaceutical Innovation Program

SAN DIEGO, CA, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye” or the “Company”), a biopharmaceutical company developing proprietary, synthetic cannabinoid-derived...